Alkermes plc. Contracts Revenue (Deprecated 2018-01-31)
Alkermes plc. (ALKS) reported Contracts Revenue (Deprecated 2018-01-31) of $7.23 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-16.
Discontinued › Income Statement › Other Income
us-gaap:ContractsRevenue · last filed 2018-02-16
- Alkermes plc. contracts revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $4.73M, a 1725.87% increase year-over-year.
- Alkermes plc. contracts revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.03M, a 443.39% increase year-over-year.
- Alkermes plc. contracts revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $833.00K, a 36.11% increase year-over-year.
- Alkermes plc. contracts revenue (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $643.00K, a 48.19% decline year-over-year.
- Alkermes plc. contracts revenue (deprecated 2018-01-31) for fiscal 2017 was $7.23M, a 214.30% increase from fiscal 2016.
- Alkermes plc. contracts revenue (deprecated 2018-01-31) for fiscal 2016 was $2.30M, a 42.75% decline from fiscal 2015.
- Alkermes plc. contracts revenue (deprecated 2018-01-31) for fiscal 2015 was $4.02M, a 48.16% decline from fiscal 2014.
- Alkermes plc. contracts revenue (deprecated 2018-01-31) for fiscal 2014 was $7.75M.
| Period end | Contracts Revenue (Deprecated 2018-01-31) 3 month | Contracts Revenue (Deprecated 2018-01-31) 6 month | Contracts Revenue (Deprecated 2018-01-31) 9 month | Contracts Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $5.76M derived: sum of 2 quarters · filed 2018-02-16 | $6.59M derived: sum of 3 quarters · filed 2018-02-16 | $7.23M 10-K · filed 2018-02-16 |
| 2017-09-30 | $1.03M 10-Q · filed 2017-10-26 | $1.86M derived: sum of 2 quarters · filed 2017-10-26 | $2.50M 10-Q · filed 2017-10-26 | $2.76M derived: sum of 4 quarters · filed 2018-02-16 |
| 2017-06-30 | $833.00K 10-Q · filed 2017-07-27 | $1.48M 10-Q · filed 2017-07-27 | $1.74M derived: sum of 3 quarters · filed 2018-02-16 | $1.92M derived: sum of 4 quarters · filed 2018-02-16 |
| 2017-03-31 | $643.00K 10-Q · filed 2017-04-27 | $902.00K derived: sum of 2 quarters · filed 2018-02-16 | $1.09M derived: sum of 3 quarters · filed 2018-02-16 | $1.70M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-12-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $448.00K derived: sum of 2 quarters · filed 2018-02-16 | $1.06M derived: sum of 3 quarters · filed 2018-02-16 | $2.30M 10-K · filed 2018-02-16 |
| 2016-09-30 | $189.00K 10-Q · filed 2017-10-26 | $801.00K derived: sum of 2 quarters · filed 2017-10-26 | $2.04M 10-Q · filed 2017-10-26 | $3.01M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $612.00K 10-Q · filed 2017-07-27 | $1.85M 10-Q · filed 2017-07-27 | $2.83M derived: sum of 3 quarters · filed 2018-02-16 | $3.50M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $1.24M 10-Q · filed 2017-04-27 | $2.21M derived: sum of 2 quarters · filed 2018-02-16 | $2.89M derived: sum of 3 quarters · filed 2018-02-16 | $3.93M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $972.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $1.65M derived: sum of 2 quarters · filed 2018-02-16 | $2.69M derived: sum of 3 quarters · filed 2018-02-16 | $4.02M 10-K · filed 2018-02-16 |
| 2015-09-30 | $678.00K 10-Q · filed 2016-11-02 | $1.71M derived: sum of 2 quarters · filed 2016-11-02 | $3.05M 10-Q · filed 2016-11-02 | $5.32M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $1.04M 10-Q · filed 2016-07-28 | $2.37M 10-Q · filed 2016-07-28 | $4.64M derived: sum of 3 quarters · filed 2017-02-17 | $6.81M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $1.33M 10-Q · filed 2016-04-28 | $3.61M derived: sum of 2 quarters · filed 2017-02-17 | $5.77M derived: sum of 3 quarters · filed 2017-02-17 | $7.23M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $4.44M derived: sum of 2 quarters · filed 2017-02-17 | $5.90M derived: sum of 3 quarters · filed 2017-02-17 | $7.75M 10-K · filed 2017-02-17 |
| 2014-09-30 | $2.16M 10-Q · filed 2015-10-29 | $3.63M derived: sum of 2 quarters · filed 2015-10-29 | $5.48M 10-Q · filed 2015-10-29 | $6.67M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $1.46M 10-Q · filed 2015-07-30 | $3.32M 10-Q · filed 2015-07-30 | $4.50M derived: sum of 3 quarters · filed 2016-02-25 | $6.51M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $1.85M 10-Q · filed 2015-04-30 | $3.04M derived: sum of 2 quarters · filed 2016-02-25 | $5.05M derived: sum of 3 quarters · filed 2016-02-25 | $6.51M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $1.19M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | $3.19M derived: sum of 2 quarters · filed 2016-02-25 | $4.66M 10-K · filed 2016-02-25 | $6.53M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-09-30 | $2.00M 10-Q · filed 2014-10-29 | $3.47M 10-Q · filed 2013-10-31 | $5.34M 10-Q · filed 2014-10-29 | $7.06M derived: sum of 4 quarters · filed 2014-10-29 |
| 2013-06-30 | $1.46M 10-Q · filed 2014-07-31 | $3.34M 10-Q · filed 2014-07-31 | $5.06M derived: sum of 3 quarters · filed 2014-07-31 | $6.52M derived: sum of 4 quarters · filed 2014-07-31 |
| 2013-03-31 | $1.88M 10-Q · filed 2014-04-30 | $3.60M derived: sum of 2 quarters · filed 2014-04-30 | $5.05M derived: sum of 3 quarters · filed 2014-04-30 | $6.54M 10-K · filed 2015-02-24 |
| 2012-12-31 | $1.72M 10-Q · filed 2013-01-31 | $3.18M derived: sum of 2 quarters · filed 2013-10-31 | $4.66M 10-Q · filed 2013-01-31 | $13.44M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-09-30 | $1.46M 10-Q · filed 2013-10-31 | $2.95M 10-Q · filed 2013-10-31 | $11.72M derived: sum of 3 quarters · filed 2014-02-27 | $13.99M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $1.49M 10-Q · filed 2013-07-25 | $10.26M derived: sum of 2 quarters · filed 2014-02-27 | $12.53M derived: sum of 3 quarters · filed 2014-02-27 | $20.58M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $8.77M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $11.04M derived: sum of 2 quarters · filed 2014-02-27 | $19.09M derived: sum of 3 quarters · filed 2014-02-27 | $22.35M 10-KT · filed 2014-02-27 |
| 2011-12-31 | $2.27M 10-Q · filed 2013-01-31 | $10.32M derived: sum of 2 quarters · filed 2013-01-31 | $13.57M 10-Q · filed 2013-01-31 | $13.72M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-09-30 | $8.05M 10-Q · filed 2012-11-01 | $11.31M 10-Q · filed 2012-11-01 | $11.45M derived: sum of 3 quarters · filed 2013-05-23 | $11.77M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-06-30 | $3.26M 10-Q · filed 2012-07-26 | $3.40M derived: sum of 2 quarters · filed 2013-05-23 | $3.71M derived: sum of 3 quarters · filed 2013-05-23 | $3.87M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-03-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $457.00K derived: sum of 2 quarters · filed 2013-05-23 | $612.00K derived: sum of 3 quarters · filed 2013-05-23 | $880.00K 10-K · filed 2013-05-23 |
| 2010-12-31 | $314.00K 10-Q · filed 2012-02-02 | $469.00K derived: sum of 2 quarters · filed 2012-02-02 | $737.00K 10-Q · filed 2012-02-02 | |
| 2010-09-30 | $155.00K 10-Q · filed 2011-11-03 | $423.00K 10-Q · filed 2011-11-03 | ||
| 2010-03-31 | $3.12M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |